Skip to main content
. 2016 Oct 5;11(10):e0164238. doi: 10.1371/journal.pone.0164238

Table 2. Clinical information of trials using intensive chemotherapy in this study.

Study Patients (NO.) Type of Disease Median age (range) Regimen Dosage CR (%) ED (%) Myelo-suppression (%)
Cytarabine (range of dose)
100-200mg/m2/d×7d
Sun[34] 18 AML (Elderly) NR (61–82) HA HHT 1-2mg/d×14d 38.89 22.2 100
Sun[46] 12 AML (Elderly) NR (64–72) HA HHT 3-4mg/d×7d 58.33 16.7 NR
Ye[28] 25 AML (Elderly) 68 (60–77) DA DNR 40mg/d×3d 44 16 76
Guo[56] 16 AML NR (45–76) HA HHT 1-2mg/d×14d 18.75 43.7 100
Sun[70] 16 MDS/t-AML (advanced) NR (45–76) HA HHT 1-2mg/d×14d 18.75 43.7 100
Zhang[74] 20 MDS/t-AML 45 (32–75) HA HHT 3-4mg/m2/d×7d 50 NR NR
Zheng[47] 16 AML (ND) NR (30–47) HA/DA HHT 3-4mg/m2/d×7d 37.50 18.7 31.2
DNR 45mg/m2/d×3d
Tong[35] 27 AML (Elderly) NR (60–76) DA DNR 40mg/m2/d×3d 33.33 11.1 NR
Liu[20] 34 AML (ND) 62 (54–68) HA HHT 4mg/d×7d 32.35 8.82 82.3
Jia[63] 15 AML (R/R) 36 (15–41) DA DNR 45mg/m2/d×4-5d 46.67 NR NR
Yang[33] 21 AML (Elderly) 68 (60–73) DA/HA/MA DNR 40mg/m2/d×3d 33.33 28.5 NR
HHT 3-4mg/d×5-7d
MITX 5-10mg/m2/d×3d
Su[68] 33 MDS/t-AML 65 (47–85) HA HHT 2-3mg/d×7d 33.33 0 NR
Wu[48] 21 AML (R/R) 44 (18–70) MAE MITX 10mg/m2/d×3d 14.29 NR 66.6
VP-16 60mg/m2/d×5d
Deng[75] 45 MDS/t-AML (advanced) 58 (38–76) HA HHT 1mg/m2/d×14d 17.78 NR 73.3
Zhou[53] 18 AML (Elderly) 67 (60–81) MA MITX 4-6mg/m2/d×3d 38.89 11.1 NR
Zhang[54] 22 AML (Elderly) NR (61–82) HA HHT 1mg/m2/d×14d 36.36 0 NR

Abbreviations: CR = Complete response; ED = earlydeath; ND = newly diagnosed; R/R = relapsed/refractory; advanced = intermediate-2 or high risk; NR = not reported; HA = homoharringtonine (HHT) and cytarabine; DA = daunorubicin (DNR) and cytarabine; MA = mitoxantrone(MITX) and cytarabine; MAE = mitoxantrone (MITX), cytarabine and etoposide (VP-16).